-Blockers greatly reduce mortality and morbidity in
patients with CHF8 –10 and are recommended in all current
CHF guidelines.11–13 However, their use for this indication
has not penetrated most practice settings. Indeed, because
most practicing physicians were taught that -blockers are
contraindicated in CHF and because initiating these agents
is complex and time consuming, it is likely that the
incorporation of these recommendations will occur slowly
and that innovative approaches will be required to enhance
their use